Korean J Hepatol.  2001 Mar;7(1):61-67.

Efficacy of Repeated Arterial Infusion of Cisplatin and 5-Fluorouracil via a Percutaneously Implantable Port System in Advanced Hepatocellular Carcinoma

• Song HG
• Lee HC
• Song BC
• Chung YH
• Lee YS
• Yoon HK
• Sung KB
• Suh DJ

Abstract

BACKGROUND/AIMS: A prospective study was performed to evaluate the efficacy of low dose administration of cisplatin (CDDP) and 5-fluorouracil (5-FU) by repeated arterial infusion via a percutaneously implantable port system (PIPS) for advanced hepatocellular carcinoma (phase II trial).
METHODS
Ten patients with hepatocellular carcinoma belonging to TNM stage IV, but without extrahepatic spread, were enrolled. Nine patients had main portal vein thrombosis. All the patients were positive for HBsAg. Patients were repeatedly treated with an arterial infusion of CDDP and 5-FU (10 mg and 250 mg, respectively, for 5 hours on days 1-5) via a PIPS at four week intervals. The response was assessed by dynamic CT after two courses of chemotherapy.
RESULTS
Insertion of PIPS was successful in 8 of 10 patients. Two patients could not receive a second course of chemotherapy because one died of progressive hepatic failure and the other developed local infection and pseudoaneurysm formation. All the remaining 6 patients exhibited tumor progression after two courses of chemotherapy. The median survival time was 89 days (range, 59-204). The causes of death were progressive hepatic failure in one patient and uncontrolled esophageal variceal bleeding in one patient.
CONCLUSIONS
Arterial infusion chemotherapy with CDDP and 5-FU via a PIPS was not an effective treatment for patients with advanced hepatocellular carcinoma.

Keyword

Neoplasm/Liver/Hepatocellular carcinoma; Percutaneously implantable port system; Chemotherapy

MeSH Terms

Aneurysm, False
Carcinoma, Hepatocellular*
Cause of Death
Cisplatin*
Drug Therapy
Esophageal and Gastric Varices
Fluorouracil*
Hepatitis B Surface Antigens
Humans
Liver Failure
Prospective Studies
Venous Thrombosis
Cisplatin
Fluorouracil
Hepatitis B Surface Antigens